Allergan Aesthetics, an AbbVie company, positioned the undetectable era as the next phase for hyaluronic acid injectables at the Aesthetic & Anti-Aging Medicine World Congress 2026 in Monaco.
The company presented global research it commissioned, Layered Beauty: The New Aesthetic Mindset, based on consumer surveys, social listening and healthcare professional interviews, which the company claims shows a shift toward personalized, natural-looking outcomes and integrated multimodal treatment plans.
The announcement emphasized the JUVÉDERM Collection of Fillers as a central, market-leading HA portfolio and introduced AA Signature, a treatment approach designed to support multimodal facial harmonization and practitioner training programs.
Allergan Aesthetics is marking more than 10 years of MD Codes with the launch of MD Codes: A Decade of Excellence, described as a compendium of 34 clinical case studies intended as a resource for healthcare professionals. The release reiterates the company’s commitment to practitioner education, product versatility and patient safety, framing HA injectables as foundational to achieving subtle, long-lasting aesthetic results.
